vs
QuidelOrtho Corp（QDEL）与Rivian Automotive, Inc.（RIVN）财务数据对比。点击上方公司名可切换其他公司
Rivian Automotive, Inc.的季度营收约是QuidelOrtho Corp的1.8倍（$1.3B vs $699.9M），Rivian Automotive, Inc.净利率更高（-63.1% vs -104.7%，领先41.7%），QuidelOrtho Corp同比增速更快（-3.7% vs -25.8%），QuidelOrtho Corp自由现金流更多（$-94.7M vs $-1.1B），过去两年Rivian Automotive, Inc.的营收复合增速更高（3.3% vs -2.9%）
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
Rivian Automotive是2009年成立的美国电动汽车制造商及汽车科技企业，主打基于自研滑板平台打造的电动SUV、皮卡及EDV电动配送货车，旗下R1T皮卡于2021年末正式开启交付，还计划于2023年底前在美国和加拿大布局专属充电网络，其平台可适配新车型也可对外授权使用。
QDEL vs RIVN — 直观对比
营收规模更大
RIVN
是对方的1.8倍
$699.9M
营收增速更快
QDEL
高出22.1%
-25.8%
净利率更高
RIVN
高出41.7%
-104.7%
自由现金流更多
QDEL
多$1.0B
$-1.1B
两年增速更快
RIVN
近两年复合增速
-2.9%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $699.9M | $1.3B |
| 净利润 | $-733.0M | $-811.0M |
| 毛利率 | — | 9.3% |
| 营业利润率 | -100.7% | -64.8% |
| 净利率 | -104.7% | -63.1% |
| 营收同比 | -3.7% | -25.8% |
| 净利润同比 | -3583.4% | -9.0% |
| 每股收益（稀释后） | $-10.78 | $-0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QDELRIVN
| Q4 25 | — | $1.3B | ||
| Q3 25 | $699.9M | $1.6B | ||
| Q2 25 | $613.9M | $1.3B | ||
| Q1 25 | $692.8M | $1.2B | ||
| Q4 24 | $707.8M | $1.7B | ||
| Q3 24 | $727.1M | $874.0M | ||
| Q2 24 | $637.0M | $1.2B | ||
| Q1 24 | $711.0M | $1.2B |
净利润QDELRIVN
| Q4 25 | — | $-811.0M | ||
| Q3 25 | $-733.0M | $-1.2B | ||
| Q2 25 | $-255.4M | $-1.1B | ||
| Q1 25 | $-12.7M | $-545.0M | ||
| Q4 24 | $-178.4M | $-744.0M | ||
| Q3 24 | $-19.9M | $-1.1B | ||
| Q2 24 | $-147.7M | $-1.5B | ||
| Q1 24 | $-1.7B | $-1.4B |
毛利率QDELRIVN
| Q4 25 | — | 9.3% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | -15.8% | ||
| Q1 25 | — | 16.6% | ||
| Q4 24 | — | 9.8% | ||
| Q3 24 | — | -44.9% | ||
| Q2 24 | — | -38.9% | ||
| Q1 24 | — | -43.8% |
营业利润率QDELRIVN
| Q4 25 | — | -64.8% | ||
| Q3 25 | -100.7% | -63.1% | ||
| Q2 25 | -29.4% | -85.5% | ||
| Q1 25 | 4.7% | -52.8% | ||
| Q4 24 | -14.2% | -38.1% | ||
| Q3 24 | 2.1% | -133.8% | ||
| Q2 24 | -18.4% | -118.7% | ||
| Q1 24 | -247.3% | -123.3% |
净利率QDELRIVN
| Q4 25 | — | -63.1% | ||
| Q3 25 | -104.7% | -75.3% | ||
| Q2 25 | -41.6% | -85.7% | ||
| Q1 25 | -1.8% | -44.0% | ||
| Q4 24 | -25.2% | -42.9% | ||
| Q3 24 | -2.7% | -125.9% | ||
| Q2 24 | -23.2% | -125.8% | ||
| Q1 24 | -239.9% | -120.1% |
每股收益（稀释后）QDELRIVN
| Q4 25 | — | $-0.66 | ||
| Q3 25 | $-10.78 | $-0.96 | ||
| Q2 25 | $-3.77 | $-0.97 | ||
| Q1 25 | $-0.19 | $-0.48 | ||
| Q4 24 | $-2.54 | $-0.67 | ||
| Q3 24 | $-0.30 | $-1.08 | ||
| Q2 24 | $-2.20 | $-1.46 | ||
| Q1 24 | $-25.50 | $-1.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.1M | $6.1B |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $2.0B | $4.6B |
| 总资产 | $5.7B | $14.9B |
| 负债/权益比越低杠杆越低 | 1.23× | — |
8季度趋势，按日历期对齐
现金及短期投资QDELRIVN
| Q4 25 | — | $6.1B | ||
| Q3 25 | $98.1M | $7.1B | ||
| Q2 25 | $151.7M | $7.5B | ||
| Q1 25 | $127.1M | $7.2B | ||
| Q4 24 | $98.3M | $7.7B | ||
| Q3 24 | $143.7M | $6.7B | ||
| Q2 24 | $107.0M | $7.9B | ||
| Q1 24 | $78.5M | $7.9B |
总债务QDELRIVN
| Q4 25 | — | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | $5.5B | ||
| Q1 24 | $2.2B | $4.4B |
股东权益QDELRIVN
| Q4 25 | — | $4.6B | ||
| Q3 25 | $2.0B | $5.1B | ||
| Q2 25 | $2.8B | $6.1B | ||
| Q1 25 | $3.0B | $6.2B | ||
| Q4 24 | $3.0B | $6.6B | ||
| Q3 24 | $3.2B | $5.9B | ||
| Q2 24 | $3.2B | $6.8B | ||
| Q1 24 | $3.3B | $8.1B |
总资产QDELRIVN
| Q4 25 | — | $14.9B | ||
| Q3 25 | $5.7B | $15.2B | ||
| Q2 25 | $6.4B | $15.6B | ||
| Q1 25 | $6.5B | $15.5B | ||
| Q4 24 | $6.4B | $15.4B | ||
| Q3 24 | $6.8B | $14.3B | ||
| Q2 24 | $6.7B | $15.4B | ||
| Q1 24 | $6.7B | $15.7B |
负债/权益比QDELRIVN
| Q4 25 | — | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | 0.81× | ||
| Q1 24 | 0.68× | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-45.5M | $-681.0M |
| 自由现金流经营现金流 - 资本支出 | $-94.7M | $-1.1B |
| 自由现金流率自由现金流/营收 | -13.5% | -89.0% |
| 资本支出强度资本支出/营收 | 7.0% | 36.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-153.1M | $-2.5B |
8季度趋势，按日历期对齐
经营现金流QDELRIVN
| Q4 25 | — | $-681.0M | ||
| Q3 25 | $-45.5M | $26.0M | ||
| Q2 25 | $-46.8M | $64.0M | ||
| Q1 25 | $65.6M | $-188.0M | ||
| Q4 24 | $63.7M | $1.2B | ||
| Q3 24 | $117.9M | $-876.0M | ||
| Q2 24 | $-97.9M | $-754.0M | ||
| Q1 24 | $-700.0K | $-1.3B |
自由现金流QDELRIVN
| Q4 25 | — | $-1.1B | ||
| Q3 25 | $-94.7M | $-421.0M | ||
| Q2 25 | $-84.3M | $-398.0M | ||
| Q1 25 | $9.4M | $-526.0M | ||
| Q4 24 | $16.5M | $856.0M | ||
| Q3 24 | $71.4M | $-1.2B | ||
| Q2 24 | $-133.2M | $-1.0B | ||
| Q1 24 | $-66.8M | $-1.5B |
自由现金流率QDELRIVN
| Q4 25 | — | -89.0% | ||
| Q3 25 | -13.5% | -27.0% | ||
| Q2 25 | -13.7% | -30.5% | ||
| Q1 25 | 1.4% | -42.4% | ||
| Q4 24 | 2.3% | 49.4% | ||
| Q3 24 | 9.8% | -131.9% | ||
| Q2 24 | -20.9% | -89.6% | ||
| Q1 24 | -9.4% | -126.5% |
资本支出强度QDELRIVN
| Q4 25 | — | 36.0% | ||
| Q3 25 | 7.0% | 28.7% | ||
| Q2 25 | 6.1% | 35.5% | ||
| Q1 25 | 8.1% | 27.3% | ||
| Q4 24 | 6.7% | 18.9% | ||
| Q3 24 | 6.4% | 31.7% | ||
| Q2 24 | 5.5% | 24.4% | ||
| Q1 24 | 9.3% | 21.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
RIVN
| Automotive Segment | $839.0M | 65% |
| Software And Services Segment | $447.0M | 35% |
| Regulatory Credits | $30.0M | 2% |
